Goodwin Advises Lakefront Biotherapeutics on Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics

The Life Sciences team advised Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) (“Lakefront”) on the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV, a Belgium-based biotechnology company developing next-generation armed CAR-T therapies for cancer. The terms of the agreement include an upfront payment of and the potential for up to $230 million in milestone payments and a low-single-digit royalty to Lakefront. The transferred preclinical assets comprise multi-targeting and armed CAR-T constructs designed to improve the potency and persistence of CAR-Ts and prevent cancer treatment resistance in hematological and solid tumors of high unmet need. Armed Cell Therapeutics BV will independently advance these programs.

Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The company has established a clinical stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases. Backed by deep dealmaking expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high-quality assets with clear potential to deliver meaningful patient impact and long-term shareholder value.

The Goodwin team was led by Paul Rosie, Morag Peberdy, Lucy Charlton, Janet Hsueh, and Michael Bison.

For more information on the deal, please read the press release.